TargetMol

BTG-1640

Product Code:
 
TAR-T26915
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26915-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26915-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26915-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BTG-1640 is used potentially for the treatment of anxiety and panic disorder.
CAS:
152538-59-5
Formula:
C15H19NO2
Molecular Weight:
245.322
Purity:
0.98
SMILES:
[H][C@@]12CCCC(=O)[C@]1([H])[C@H](Cc1ccccc1)N(C)O2

References

1. Saletu B, Anderer P, Wolzt M, Nosiska D, Assandri A, Noseda E, Nannipieri F, Saletu-Zyhlarz GM. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography). Neuropsychobiology. 2009;59(2):110-22. doi: 10.1159/000212380. PubMed PMID: 19365151. 2. Saletu-Zyhlarz GM, Anderer P, Wolzt M, Semlitsch HV, Assandri A, Nessi P, Nannipieri F, Rosini S, Saletu B. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings. Neuropsychobiology. 2009;59(2):100-9. doi: 10.1159/000212379. PubMed PMID: 19365150. 3. Anderer P, Saletu B, Wolzt M, Culic S, Assandri A, Nannipieri F, Rosini S, Saletu-Zyhlarz GM. Double-blind, placebo-controlled, multiple-ascending-dose study on the effects of ABIO-08/01, a novel anxiolytic drug, on perception and cognition, utilizing event-related potential mapping and low-resolution brain electromagnetic tomography. Hum Psychopharmacol. 2008 Apr;23(3):243-54. doi: 10.1002/hup.920. PubMed PMID: 18181252.